COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Risk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., Nedoszytko, B., Siebenhaar, F., Sperr, W. R., Oude Elberink, J. N. G., et al. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.01.006 · Cited by 225 · cited 1×
“…reactions in patients with mast cell disease (such as mastocytosis) nor those who meet published criteria for mast cell activation syndrome (MCAS); 22 in the absence of any data, we recommend that such patients can be vaccinated, but may bene fi t from extended observation of at least 30 min.”
Bruusgaard‐Mouritsen, M. A., Johansen, J. D., & Garvey, L. H. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13822 · Cited by 86
Metadata
- Authors
- Turner, P. J., Ansotegui, I. J., Campbell, D. E., Cardona, V., Ebisawa, M., El-Gamal, Y., Fineman, S., Geller, M., Gonzalez-Estrada, A., Greenberger, P. A., Leung, A. S. Y., Levin, M. E., Muraro, A., Sánchez Borges, M., Senna, G., Tanno, L. K., Thong, B. Y.-H., & Worm, M.
- Venue
- World Allergy Organization Journal
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 14
- Issue
- 2
- Pages
- 100517
- ISSN
- 1939-4551 (ISSN-L)
- OpenAlex
- W3126621205
- Cited by
- 169
- References
- 4
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. https://app.cochat.ai/papers/10.1016/j.waojou.2021.100517
- The paper
- Turner, P. J., Ansotegui, I. J., Campbell, D. E., Cardona, V., Ebisawa, M., El-Gamal, Y., Fineman, S., Geller, M., Gonzalez-Estrada, A., Greenberger, P. A., Leung, A. S. Y., Levin, M. E., Muraro, A., Sánchez Borges, M., Senna, G., Tanno, L. K., Thong, B. Y.-H., & Worm, M. (2021). COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal. https://doi.org/10.1016/j.waojou.2021.100517
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.